Reports
Global Cystic Fibrosis Treatment Market Share, Size, Growth, Analysis, Trends, Insights, Forecast: By Treatment Method: Drug Treatment, Airway Clearance Techniques, Pulmonary Rehabilitation, Surgical Methods, Others; By Classification; By Route of Administration; By Distribution Channels; Regional Analysis; Supplier Landscape; 2023-2031
Global Cystic Fibrosis Treatment Market Outlook
The global cystic fibrosis treatment market attained a value of USD 8.3 billion in 2022 and is expected to reach a value of about USD 25.7 billion by 2031. The market is estimated to grow at a CAGR of 13.4% during the forecast period of 2023-2031. The availability of specific drug therapies and molecular prosthetics for the treatment of cystic fibrosis are anticipated to be the market’s primary growth drivers.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cystic Fibrosis Insights
Cystic fibrosis (CF) is an inherited disease that causes severe damage to the lungs, digestive system, and other body organs. Cystic fibrosis affects the cells responsible for the production of mucus, sweat, and digestive juices. Normally, these secreted fluids are thin and slippery, however, in people with cystic fibrosis, a faulty gene causes the secretions to become sticky and thick. These secretions, rather than acting as lubricants, clog tubes, ducts, and passageways, particularly in the lungs and pancreas.
Despite the fact that cystic fibrosis is a progressive disease that necessitates daily care, people with CF are usually able to do all the daily activities. Patients suffering from CF now have a better quality of life than previous generations of CF patients. Due to the advancements in screening and treatment, people with CF can now live in their mid- to late-30s or 40s, with some even living into their 50s.
The signs and symptoms in the respiratory and digestive systems include:
- A chronic cough that produces thick mucus (sputum)
- Wheezing
- Intolerance to Exercise
- Recurring Lung Infections
- Inflammation of the Nasal Passages or a Stuffy Nose
- Sinusitis that Recurs
The thick mucus can also obstruct the tubes that transport digestive enzymes from the pancreas to the small intestine. Without these digestive enzymes, the intestines are unable to absorb all of the nutrients in the food consumed. It often results in:
- Smelly and Greasy Stools
- Inadequate Weight Gain and Growth
- Intestinal Obstruction, especially in New-Borns
- Constipation that is chronic or severe, with frequent straining to pass stool, eventually causing part of the rectum to protrude outside the anus.
CF is caused by a mutation in the "cystic fibrosis transmembrane conductance regulator" gene, or CFTR gene. Gene regulates the movement of water and salt into and out of the cells. A sudden mutation or change in the CFTR gene causes the mucus to thicken and stickier than usual. This abnormal mucus raises the salt content of the sweat and accumulates in various organs throughout the body, including the intestines, pancreas, liver, and lungs.
According to the cystic fibrosis treatment market research report, the market can be categorized into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Treatment Method
- Drug Treatment
- Airway Clearance Technique
- Pulmonary Rehabilitation
- Surgical Methods
- Nasal and Sinus Surgery
- Bowel Surgery
- Lung Transplant
- Liver Transplant
- Others
Market Breakup by Drug Class
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- Bronchodilators
- Mucolytics
- Pancreatic Enzyme Supplement
- Others
Market Breakup by Route of Administration
- Oral Drug
- Inhaled Drug
Market Breakup by Distribution Channel
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cystic Fibrosis Therapeutic Landscape
According to the Cystic Fibrosis Foundation, over 30,000 people in the United States have cystic fibrosis, and an additional 1,000 are diagnosed each year. Since CF is a progressive disease, it worsens over time and thus the treatment is extremely crucial.
Although there is no cure for CF, there are several treatments that can help relieve the symptoms and reduce the risk of complications. The available treatments include antibiotics, mucus-thinning medication, NSAIDs, Bronchodilators, CFTR, whereas the surgical procedures include bowel surgery, feeding tube, and double lung transplant. Other than medications and surgical treatment, chest physical therapy and home care are also included in the management of this disease.
Drivers and Constraints
The market growth has been aided by an increase in the number of cystic fibrosis patients worldwide. Cystic fibrosis pharmacotherapy has resulted in a number of advancements in the treatment of this ailment, which is positively impacting the market growth.
Cystic fibrosis treatment market growth is expected to be driven by the rise in non-profit initiatives, increase in government-backed legislation, and increases in research and development funding. Researchers are expected to increase their investment in research and development activities in order to fuel market growth. There are a number of drugs in development, including Symdeko, VX-561, ELX-02, and ABBV-3067.
In terms of region, the global market is expected to be dominated by North America. The dominance can be attributed to the rapid increase in cystic fibrosis cases in the region, an increase in patients with various respiratory diseases affecting cystic fibrosis, and higher healthcare costs.
Europe is in the second position, following North America in terms of demand for advanced drugs due to the prevalence of the disease and the increased use of advanced drugs to achieve better results.
On the other hand, there are some factors which have been restricting the growth of the market. Along with the positive effects these medicines provide, there are some side effects that come with these medicines. These undesirable side effects include upper respiratory tract infections, liver problems, chest pain, and an increase in blood pressure, among other issues, and may obstruct the growth of the treatment market.
Clinical Trial
In the past few years, it has been observed that patients with cystic fibrosis have been able to live longer due to the rapid improvements in clinical care. There are some European countries where life expectancy has increased to 30-40 years.
The growth of the cystic fibrosis treatment market is driven by the treatment of lung diseases and improved nutrition. The current treatment strategies can be improved by identifying new effective agents. Various clinical trials are underway for several drugs that are suspected of being effective in combating CFTR dysfunction. Cystic fibrosis is a condition that affects many organs.
The development of drugs to treat lung disease, dyspepsia, and pancreatic malabsorption has become increasingly important. Researchers are developing drugs in many fields, including anti-inflammatory treatments, ion channel blockers, and genetic therapies.
A major objective of pancreatic insufficiency treatment is to develop pancreatic enzymes that work most efficiently. A variety of treatments for cystic fibrosis are driving the growth of the cystic fibrosis treatment market.
- Treatment with nebulized antibiotics for chronic lung disease reduces lung damage and improves lung function.
- There is a reduction in exacerbations and improved quality of life in a randomized controlled trial of azithromycin FEV1 treatment.
- The use of Ursodeoxycholic acid (URSO) in patients has been shown to normalize liver enzyme levels.
- Several clinical trials have been conducted to restore CFTR function in patients suffering from disease. Transient and moderate effects of gene transfer were observed on CFTR function. There have been improvements to gene transfer agents and plasmids, and clinical trials will commence shortly.
The cystic fibrosis treatment market is experiencing rapid growth due to an increasing demand for research.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global cystic fibrosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Genentech, Inc.
- Gilead Sciences, Inc.
- Novartis International AG
- Vertex Pharmaceuticals Incorporated
- Johnson & Johnson Services, Inc
- Allergan Plc.
- Nestle Health Science S.A.
- AbbVie Inc.
- Horizon Therapeutics Plc.
- Chiesi Farmaceutici S.P.A.
- Pharmaxis Ltd.
- Teva Pharmaceuticals Industries Ltd
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Method |
|
| Breakup by Classification |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Cystic Fibrosis Overview
4.1 Drug Overview
4.2 Pharmacodynamics
4.2.1 Pharmacokinetics
4.2.2 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Investment Scenarios
6.5 Regulatory Framework
6.5.1 Regulatory Overview
6.5.1.1 US FDA
6.5.1.2 EU EMA
6.5.1.3 INDIA CDSCO
6.5.1.4 JAPAN PMDA
6.5.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global Cystic Fibrosis Treatment Market
8.1 Global Cystic Fibrosis Treatment Market Overview
8.2 Global Cystic Fibrosis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Cystic Fibrosis Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Cystic Fibrosis Treatment Market Forecast Value (2023-2031)
8.3 Global Cystic Fibrosis Treatment Market by Treatment Method
8.3.1 Market Overview
8.3.1.1 Drug Treatment
8.3.1.2 Airway Clearance Techniques
8.3.1.3 Pulmonary Rehabilitation
8.3.1.4 Surgical Methods
8.3.1.4.1 Nasal and Sinus Surgery
8.3.1.4.2 Bowel Surgery
8.3.1.4.3 Lung Transplant
8.3.1.4.4 Liver Transplant
8.3.1.5 Others
8.4 Global Cystic Fibrosis Treatment Market by Classification
8.4.1 Market Overview
8.4.1.1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
8.4.1.2 Bronchodilators
8.4.1.3 Mucolytics
8.4.1.4 Pancreatic Enzyme Supplements
8.4.1.5 Others
8.5 Global Cystic Fibrosis Treatment Market by Route of Administration
8.5.1 Market Overview
8.5.1.1 Oral Drug
8.5.1.2 Inhaled drug
8.6 Global Cystic Fibrosis Treatment Market by Distribution Channels
8.6.1 Market Overview
8.6.1.1 Hospital Based Pharmacies
8.6.1.2 Online Pharmacies
8.6.1.3 Retail Pharmacies
8.7 Global Cystic Fibrosis Treatment Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 North America Cystic Fibrosis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Cystic Fibrosis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Cystic Fibrosis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Cystic Fibrosis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Cystic Fibrosis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Cystic Fibrosis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter’s Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Genentech, Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievement
15.1.4 Merger and Acquisitions
15.1.5 Certifications
15.2 Gilead Sciences, Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievement
15.2.4 Merger and Acquisitions
15.2.5 Certifications
15.3 Novartis International AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievement
15.3.4 Merger and Acquisitions
15.3.5 Certifications
15.4 Vertex Pharmaceuticals Incorporated
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievement
15.4.4 Merger and Acquisitions
15.4.5 Certifications
15.5 Johnson & Johnson Services, Inc
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievement
15.5.4 Merger and Acquisitions
15.5.5 Certifications
15.6 Allergan Plc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievement
15.6.4 Merger and Acquisitions
15.6.5 Certifications
15.7 Nestle Health Science S.A.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievement
15.7.4 Merger and Acquisitions
15.7.5 Certifications
15.8 AbbVie Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievement
15.8.4 Merger and Acquisitions
15.8.5 Certifications
15.9 Horizon Therapeutics Plc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievement
15.9.4 Merger and Acquisitions
15.9.5 Certifications
15.10 Chiesi Farmaceutici S.P.A.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievement
15.10.4 Merger and Acquisitions
15.10.5 Certifications
15.11 Pharmaxis Ltd.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievement
15.11.4 Merger and Acquisitions
15.11.5 Certifications
15.12 Teva Pharmaceuticals Industries Ltd
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievement
15.12.4 Merger and Acquisitions
15.12.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global Cystic Fibrosis Treatment Market- Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global market for cystic fibrosis treatment attained a value of USD 8.3 billion in 2022.
The global market is likely to grow at a CAGR of 13.4% during the forecast period of 2023-2031 to attain a value of USD 25.7 billion by 2031.
The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.
Factors predicted to expand the market size include the rising prevalence of genetic disorders worldwide which will expand the market of cystic fibrosis treatment.
Hospital is the end-user that is dominating the global market.
The key players in the market include Genentech, Inc., Gilead Sciences, Inc., Novartis International AG, Vertex Pharmaceuticals Incorporated, Johnson & Johnson Services, Inc, Allergan Plc., Nestle Health Science S.A., AbbVie Inc., Horizon Therapeutics Plc., Chiesi Farmaceutici S.P.A., Pharmaxis Ltd., and Teva Pharmaceuticals Industries Ltd , among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER